2,6-Dimethoxyamphetamine
Pharmaceutical compound
From Wikipedia, the free encyclopedia
2,6-Dimethoxyamphetamine (2,6-DMA), also known as DMA-5, is a drug of the phenethylamine and amphetamine families.[1] It is one of the positional isomers of dimethoxyamphetamine.[1]
| Clinical data | |
|---|---|
| Other names | 2,6-DMA; DMA-5 |
| Drug class | Serotonin receptor modulator |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C11H17NO2 |
| Molar mass | 195.262 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
The drug has not been tested in humans and its effects in humans are unknown.[1]
2,6-DMA showed very low affinity for serotonin receptors in rat stomach fundus strips (A2 = 8,130 nM).[1][2] In a subsequent study, it showed no affinity for the serotonin 5-HT2A or 5-HT2C receptors (Ki = >10,000 nM).[3] 2,6-DMA only partially substituted for DOM in rodent drug discrimination tests, with a maximum responding of 41% and behavioral disruption at higher doses.[4][5] It did not substitute for dextroamphetamine in these tests.[5][6]
The chemical synthesis of 2,6-DMA has been described.[1]
2,6-DMA was first described in the scientific literature by Alexander Shulgin by 1969.[7] At that time, he had not yet synthesized it and did not report its effects.[7] 2,6-DMA is a positional isomer of 2,5-dimethoxyamphetamine (2,5-DMA) and hence is a Schedule I controlled substance in the United States.[1]